Kyverna Q1 net loss $26.7M; cash $369.8M; treated 30 patients cumulatively

Kyverna Therapeutics, Inc.

2024-Q1 EPS reported -$1.12

Net loss of $26.7M ($1.12 per share) vs net loss of $11.1M ($12.10 per share) in Q1 2023.
Cash, cash equivalents and marketable securities $369.8M as of March 31, 2024, including $336.2M net IPO proceeds.
Treated 30 patients cumulatively with KYV-101: 8 myasthenia gravis, 7 lupus nephritis, 4 multiple sclerosis.
KYV-101 granted FDA Orphan Drug Designation for myasthenia gravis; upcoming data at EULAR, ECTRIMS, ACR.
Net cash used in operations $25.5M in Q1 2024 vs $11.5M in Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kyverna Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income a net loss of $26.7 million, EPS a net loss per common share of $1.12.

Period: the first quarter ended March 31, 2024
Net income: a net loss of $26.7 million
EPS: a net loss per common share of $1.12
Result: reported results

Exact text from the filing

For the quarter ended March 31, 2024, the company reported a net loss of $26.7 million, or a net loss per common share of $1.12

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Kyverna Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-059613

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.